BEIJING, June 1 (Xinhua) -- The following are the updates on the global fight against the COVID-19 pandemic.
- - - -
YANGON -- Myanmar's Foreign Affairs Ministry Monday announced extension of temporary entry restrictions for travellers from all countries until June 15, as part of measures to contain the spread of COVID-19 outbreak.
The extension will be effective to the ministry's announcements of precautionary measures for the travellers which were set to be in force until May 31.
- - - -
THE HAGUE -- The Netherlands reopened restaurants, cafes, theaters, concert halls, museums and cinemas on Monday after two and a half months' COVID-19 lockdown.
According to the rules, a maximum of 30 people are allowed in restaurants, cafes, theaters, concert halls and cinemas, as long as the 1.5-meter social distancing rules can be kept. A maximum of two people who are not from the same household can sit together at one table.
- - - -
LUSAKA -- Zambia reported 32 new COVID-19 cases in the last five days, bringing the cumulative cases to 1,089, health authorities said on Monday.
The country conducted 3,961 tests in the last five days from which the 32 cases were picked from.
- - - -
KATHMANDU -- With the confirmation of 226 new cases on Monday, Nepal has seen the highest single day spike of COVID-19 cases, and the total tally has surged to 1,798.
According to the Ministry of Health and Population (MoHP), 213 males and 13 females tested positive for COVID-19 on Monday.
- - - -
ADDIS ABABA -- Ethiopia on Monday reported 85 more confirmed COVID-19 cases, bringing the tally to 1,257 in the country.
All 85 new cases, 51 males and 34 females, are Ethiopian nationals, the Federal Ministry of Health said in a statement.
- - - -
BEIJING -- China's inactivated COVID-19 vaccine is expected to finish clinical trials and get ready for the market as early as the end of this year or early next year, according to developer China National Biotec Group (CNBG).
As a subsidiary of the China National Pharmaceutical Group (Sinopharm), CNBG has two inactivated COVID-19 vaccines under Phase-2 clinical trials and has increased its vaccine production capacity. Enditem
